1:33
ALL diagnostics: challenges and considerations
Torsten Haferlach
3:37
Results of the COG AALL0434 trial for T-cell malignancies
Kimberly Dunsmore
1:17
The ALL frontier: should T-ALL be classed as a different disease?
Elizabeth Macintyre
4:26
Making an IMPACT in ALL therapy: how can cure rates be improved?
David Marks
0:51
Nelarabine as first-line treatment for T-cell ALL: facing the problem up-front
David Marks
10:31
Recent subtypes of ALL: Ph-like ALL and ETP ALL
Anjali Advani et al.
0:49
The future of inhibiting Bcl2 for the treatment of T-ALL
Kim Kampen
1:07
The serine biosynthesis pathway and its role in T-ALL
Kim Kampen
1:22
Understanding the RPL10 R98S mutation in T-ALL
Kim Kampen
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals